Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties

A solid, controlled release, oral dose form of an active pharmaceutical wherein said dose form comprises an analgesically effective amount of an opioid salt wherein said opioid salt is selected from the group consisting of:

• amorphous oxycodone pamoate characterized by at least one method selected from the group consisting of:
• a differential scanning calorimetery thermogram of FIG. 1;
• an FTIR of FIG. 2;
• and
• an X-ray diffraction diffractogram of FIG. 3;
• polymorphic oxycodone pamoate characterized by at least one method selected from the group consisting of:
• a differential scanning calorimetery thermogram of FIG. 4;
• an FTIR of FIG. 5;
• and
• an X-ray diffraction diffractogram of FIG. 6;
• polymorphic oxycodone pamoate characterized by at least one method selected from the group consisting of:
• a differential scanning calorimetery thermogram of FIG. 98;
• an FTIR of FIG. 99;
• and
• an X-ray diffraction diffractogram of FIG. 100;
• and
• hydrocodone xinafoate characterized by at least one method selected from the group consisting of:
• a differential scanning calorimetery thermogram of FIG. 16;
• an FTIR of FIG. 17;
• and
• an X-ray diffraction diffractogram of FIG. 18;
• and
• wherein said opiod salt has a release profile when measured as a drug substance defined by at least 12.5 wt % to no more than 42.5 wt % of said opioid being bioavailable at 1 hour at a biological pH measured in USP water and wherein said opioid bioavailability is not increased in the presence of USP alcohol in said USP water at said biological pH.